Skip to main content
. 2017 Oct 24;1(23):2105–2114. doi: 10.1182/bloodadvances.2017006866

Figure 6.

Figure 6.

NK cell dynamic metrics and PFS with daratumumab treatment. HRs according to PFS for patients divided into quartiles based on (top) baseline NK-cell count, (middle) maximum NK-cell reduction, and (bottom) NK-cell recovery rate. The numbers on the right show the mean and 95% confidence interval for the HR for that quartile and the number of patients (n) and PFS events in each group. Q1 was used as the reference group.